Compare · TCMD vs WST
TCMD vs WST
Side-by-side comparison of Tactile Systems Technology Inc. (TCMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TCMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 38.8x TCMD ($572.9M).
- Over the past year, TCMD is up 149.0% and WST is up 42.4% - TCMD leads by 106.6 points.
- WST has been more active in the news (4 items in the past 4 weeks vs 2 for TCMD).
- WST has more recent analyst coverage (16 ratings vs 9 for TCMD).
- Company
- Tactile Systems Technology Inc.
- West Pharmaceutical Services Inc.
- Price
- $25.50+0.43%
- $318.69+1.36%
- Market cap
- $572.9M
- $22.22B
- 1M return
- -2.02%
- -1.02%
- 1Y return
- +149.02%
- +42.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 2
- 4
- Recent ratings
- 9
- 16
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest TCMD
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
- CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $113,404 worth of shares (4,631 units at $24.49), decreasing direct ownership by 3% to 130,188 units (SEC Form 4)
- SEC Form 144 filed by Tactile Systems Technology Inc.
- Director Asbury Valerie L. was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Huggenberger Raymond was granted 6,521 shares, increasing direct ownership by 12% to 62,841 units (SEC Form 4)
- Director King Laura G. was granted 6,521 shares, increasing direct ownership by 34% to 25,569 units (SEC Form 4)
- Director Pearson Andrea was granted 6,521 shares, increasing direct ownership by 765% to 7,373 units (SEC Form 4)
- Director Shafer David Brent was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Volkart Carmen B was granted 6,521 shares, increasing direct ownership by 17% to 44,219 units (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)